Exertional Desaturation During the 6-Minute Walk Test vs Daily Life in People With Fibrotic Interstitial Lung Disease.

Competing Interests: Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: M. H. reports a relationship with Thoracic Society of Australia and New Zealand that includes funding grants and relationship with Centre of Research Excellence in Pulmonary Fibrosis that includes travel reimbursement. I. G. reports a relationship with Boehringer Ingelheim Ltd that includes board membership, a relationship with Lassen Therapeutics 1, Inc, that includes consulting or advisory, a relationship with Tian Li that includes consulting or advisory, and a relationship with Avalyn Pharma Inc that includes consulting or advisory. J. A. M reports a relationship with Boehringer Ingelheim Ltd that includes speaking and lecture fees. N. S. L. G. reports a relationship with Boehringer Ingelheim GmbH that includes consulting or advisory and speaking and lecture fees. N. S. L. G. also reports a relationship with AstraZeneca Pharmaceuticals LP that includes speaking and lecture fees and a relationship with National Health and Medical Research Council that includes funding grants. T. J. C. declares a relationship with institutional grant Boehringer Ingleheim and Roche that includes advisory board and speaker fees, a relationship with Bristol Myers Squibb, Vicore, DevPro, Bridge Biotherapeutics that includes advisory board, and a relationship with Biogen, Galapagos, Avalyn Pharma that includes institutional grant funding. C. F. M., D. C. C., M. E., T. J. C., and A. E. H report administrative support was provided by BOC Australia. None declared (A. T. B., M. S.).